Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 120 articles:
HTML format
Text format



Single Articles


    October 2018
  1. LIU L, Shi M, Wang Z, Lu H, et al
    A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.
    BMC Cancer. 2018;18:966.
    PubMed     Text format     Abstract available


  2. QIN RS, Zhang ZH, Zhu NP, Chen F, et al
    Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    BMC Cancer. 2018;18:967.
    PubMed     Text format     Abstract available


  3. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Text format     Abstract available


  4. TACHIHARA M, Negoro S, Inoue T, Tamiya M, et al
    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    BMC Cancer. 2018;18:946.
    PubMed     Text format     Abstract available


    September 2018
  5. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Engaging the older cancer patient; Patient Activation through Counseling, Exercise and Mobilization - Pancreatic, Biliary tract and Lung cancer (PACE-Mobil-PBL) - study protocol of a randomized controlled trial.
    BMC Cancer. 2018;18:934.
    PubMed     Text format     Abstract available


  6. ANDRIANI F, Landoni E, Mensah M, Facchinetti F, et al
    Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer.
    BMC Cancer. 2018;18:899.
    PubMed     Text format     Abstract available


  7. YIN Z, Cui Z, Li H, Li J, et al
    Polymorphisms in the H19 gene and the risk of lung Cancer among female never smokers in Shenyang, China.
    BMC Cancer. 2018;18:893.
    PubMed     Text format     Abstract available


  8. BENBRAHIM Z, Antonia T, Mellas N
    EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:891.
    PubMed     Text format     Abstract available


  9. VANHOVE K, Giesen P, Owokotomo OE, Mesotten L, et al
    The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer.
    BMC Cancer. 2018;18:868.
    PubMed     Text format     Abstract available


    August 2018
  10. KIM Y, Pierce CM, Robinson LA
    Impact of viral presence in tumor on gene expression in non-small cell lung cancer.
    BMC Cancer. 2018;18:843.
    PubMed     Text format     Abstract available


  11. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Text format     Abstract available


  12. XU F, Ren X, Chen Y, Li Q, et al
    Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
    BMC Cancer. 2018;18:808.
    PubMed     Text format     Abstract available


  13. ZHANG W, Wei Y, Yu D, Xu J, et al
    Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2018;18:780.
    PubMed     Text format     Abstract available


    July 2018
  14. BUTCHER K, Kannappan V, Kilari RS, Morris MR, et al
    Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line.
    BMC Cancer. 2018;18:753.
    PubMed     Text format     Abstract available


  15. MAZZA D, Lin X, Walter FM, Young JM, et al
    The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds.
    BMC Cancer. 2018;18:754.
    PubMed     Text format     Abstract available


  16. BERG J, Halvorsen AR, Bengtson MB, Tasken KA, et al
    Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
    BMC Cancer. 2018;18:739.
    PubMed     Text format     Abstract available


  17. SHENG Y, Xu M, Li C, Xiong Y, et al
    Nm23-H1 is involved in the repair of ionizing radiation-induced DNA double-strand breaks in the A549 lung cancer cell line.
    BMC Cancer. 2018;18:710.
    PubMed     Text format     Abstract available


    June 2018
  18. WANG Y, Qu X, Kam NW, Wang K, et al
    An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.
    BMC Cancer. 2018;18:692.
    PubMed     Text format     Abstract available


  19. LI X, Zhou Q, Wang X, Su S, et al
    The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes.
    BMC Cancer. 2018;18:683.
    PubMed     Text format     Abstract available


  20. TIAN X, Ma J, Wang T, Tian J, et al
    Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer.
    BMC Cancer. 2018;18:660.
    PubMed     Text format     Abstract available


  21. HOU X, Gong R, Zhan J, Zhou T, et al
    p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:641.
    PubMed     Text format     Abstract available


  22. ZHU H, Zhang S
    Body mass index and lung cancer risk in never smokers: a meta-analysis.
    BMC Cancer. 2018;18:635.
    PubMed     Text format     Abstract available


    May 2018
  23. MARINGE C, Pashayan N, Rubio FJ, Ploubidis G, et al
    Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?
    BMC Cancer. 2018;18:615.
    PubMed     Text format     Abstract available


  24. ZENG J, Zhang H, Tan Y, Sun C, et al
    Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:611.
    PubMed     Text format     Abstract available


  25. LI H, Huang N, Zhu W, Wu J, et al
    Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    BMC Cancer. 2018;18:579.
    PubMed     Text format     Abstract available


  26. EZZELDIN N, El-Lebedy D, Darwish A, El Bastawisy A, et al
    Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.
    BMC Cancer. 2018;18:525.
    PubMed     Text format     Abstract available


  27. QUAIFE SL, Vrinten C, Ruparel M, Janes SM, et al
    Smokers' interest in a lung cancer screening programme: a national survey in England.
    BMC Cancer. 2018;18:497.
    PubMed     Text format     Abstract available


    April 2018
  28. HE F, Xiao RD, Lin T, Xiong WM, et al
    Dietary patterns, BCMO1 polymorphisms, and primary lung cancer risk in a Han Chinese population: a case-control study in Southeast China.
    BMC Cancer. 2018;18:445.
    PubMed     Text format     Abstract available


  29. MISHRA DK, Miller RA, Pence KA, Kim MP, et al
    Small cell and non small cell lung cancer form metastasis on cellular 4D lung model.
    BMC Cancer. 2018;18:441.
    PubMed     Text format     Abstract available


  30. ABBAS HHK, Alhamoudi KMH, Evans MD, Jones GDD, et al
    MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    BMC Cancer. 2018;18:423.
    PubMed     Text format     Abstract available


  31. DHONT L, Pintilie M, Kaufman E, Navab R, et al
    Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).
    BMC Cancer. 2018;18:429.
    PubMed     Text format     Abstract available


  32. AI X, Mao F, Shen S, Shentu Y, et al
    Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.
    BMC Cancer. 2018;18:407.
    PubMed     Text format     Abstract available


  33. HE W, Zhang H, Wang Y, Zhou Y, et al
    CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.
    BMC Cancer. 2018;18:400.
    PubMed     Text format     Abstract available


  34. THRIUMANI R, Zakaria A, Hashim YZH, Jeffree AI, et al
    A study on volatile organic compounds emitted by in-vitro lung cancer cultured cells using gas sensor array and SPME-GCMS.
    BMC Cancer. 2018;18:362.
    PubMed     Text format     Abstract available


    March 2018
  35. TAN PT, Aziz MIA, Pearce F, Lim WT, et al
    Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    BMC Cancer. 2018;18:352.
    PubMed     Text format     Abstract available


  36. BRUECKL WM, Achenbach HJ, Ficker JH, Schuette W, et al
    Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    BMC Cancer. 2018;18:333.
    PubMed     Text format     Abstract available


  37. FIDLER MJ, Fhied CL, Roder J, Basu S, et al
    The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    BMC Cancer. 2018;18:310.
    PubMed     Text format     Abstract available


  38. LYNCH JA, Berse B, Rabb M, Mosquin P, et al
    Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
    BMC Cancer. 2018;18:306.
    PubMed     Text format     Abstract available


  39. HAKOZAKI T, Okuma Y, Kashima J
    Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
    BMC Cancer. 2018;18:302.
    PubMed     Text format     Abstract available


  40. BRIZZI MP, La Salvia A, Tampellini M, Sonetto C, et al
    Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
    BMC Cancer. 2018;18:311.
    PubMed     Text format     Abstract available


  41. YORITA K, Tsuji K, Takano Y, Kuroda N, et al
    Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report.
    BMC Cancer. 2018;18:300.
    PubMed     Text format     Abstract available


  42. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Text format     Abstract available


  43. YAO D, Zhang L, Wu PL, Gu XL, et al
    Clinical and misdiagnosed analysis of primary pulmonary lymphoma: a retrospective study.
    BMC Cancer. 2018;18:281.
    PubMed     Text format     Abstract available


  44. RYSKA A, Berzinec P, Brcic L, Cufer T, et al
    NSCLC molecular testing in Central and Eastern European countries.
    BMC Cancer. 2018;18:269.
    PubMed     Text format     Abstract available


  45. WANG G, Guo C, Zhao H, Pan Z, et al
    TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.
    BMC Cancer. 2018;18:260.
    PubMed     Text format     Abstract available


  46. JIN BF, Yang F, Ying XM, Gong L, et al
    Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    BMC Cancer. 2018;18:259.
    PubMed     Text format     Abstract available


  47. LEE DW, Lee KH, Kim HJ, Kim TY, et al
    A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    BMC Cancer. 2018;18:252.
    PubMed     Text format     Abstract available


  48. IKEDA S, Kato T, Ogura T, Sekine A, et al
    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thorac
    BMC Cancer. 2018;18:241.
    PubMed     Text format     Abstract available


    February 2018
  49. BROGDEN KA, Parashar D, Hallier AR, Braun T, et al
    Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    BMC Cancer. 2018;18:225.
    PubMed     Text format     Abstract available


  50. SANIKINI H, Yuan JM, Butler LM, Koh WP, et al
    Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies.
    BMC Cancer. 2018;18:220.
    PubMed     Text format     Abstract available


  51. DE FONSEKA D, Arnold DT, Stadon L, Morley A, et al
    A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    BMC Cancer. 2018;18:199.
    PubMed     Text format     Abstract available


  52. DEMUTH C, Madsen AT, Weber B, Wu L, et al
    The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    BMC Cancer. 2018;18:191.
    PubMed     Text format     Abstract available


  53. CHU GCW, Lazare K, Sullivan F
    Serum and blood based biomarkers for lung cancer screening: a systematic review.
    BMC Cancer. 2018;18:181.
    PubMed     Text format     Abstract available


  54. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Text format     Abstract available


  55. OLIVIER C, Grosbois JM, Cortot AB, Peres S, et al
    Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
    BMC Cancer. 2018;18:178.
    PubMed     Text format     Abstract available


  56. MERVAI Z, Egedi K, Kovalszky I, Baghy K, et al
    Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
    BMC Cancer. 2018;18:157.
    PubMed     Text format     Abstract available


  57. WANG ZF, Ren SX, Li W, Gao GH, et al
    Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:148.
    PubMed     Text format     Abstract available


  58. SCHUETTE W, Schirmacher P, Eberhardt WEE, Dietel M, et al
    Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    BMC Cancer. 2018;18:135.
    PubMed     Text format     Abstract available


    January 2018
  59. OU JY, Fowler B, Ding Q, Kirchhoff AC, et al
    A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population.
    BMC Cancer. 2018;18:115.
    PubMed     Text format     Abstract available


  60. ARRIOLA E, Garcia Gomez R, Diz P, Majem M, et al
    Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    BMC Cancer. 2018;18:106.
    PubMed     Text format     Abstract available


  61. NARUMI Y, Yoshida R, Minami Y, Yamamoto Y, et al
    Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    BMC Cancer. 2018;18:95.
    PubMed     Text format     Abstract available


  62. MOKHLES S, Nuyttens JJME, de Mol M, Aerts JGJV, et al
    Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making.
    BMC Cancer. 2018;18:79.
    PubMed     Text format     Abstract available


  63. WU N, Ren D, Li S, Ma W, et al
    RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
    BMC Cancer. 2018;18:67.
    PubMed     Text format     Abstract available


  64. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Text format     Abstract available


  65. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Text format     Abstract available


  66. QU TT, Chen F, Wang J, Zhang YJ, et al
    PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.
    BMC Cancer. 2018;18:27.
    PubMed     Text format     Abstract available


  67. ZHOU J, Zheng J, Zhang X, Zhao J, et al
    Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    BMC Cancer. 2018;18:10.
    PubMed     Text format     Abstract available


  68. KANEDA T, Yoshioka H, Tamiya M, Tamiya A, et al
    Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    BMC Cancer. 2018;18:6.
    PubMed     Text format     Abstract available


    December 2017
  69. LIU D, Huang Y, Li L, Song J, et al
    High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    BMC Cancer. 2017;17:882.
    PubMed     Text format     Abstract available


  70. WANG D, Haley JD, Thompson P
    Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.
    BMC Cancer. 2017;17:830.
    PubMed     Text format     Abstract available


  71. BLANCO-PRIETO S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal FJ, et al
    Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis.
    BMC Cancer. 2017;17:823.
    PubMed     Text format     Abstract available


    November 2017
  72. IKEDA S, Yoshioka H, Ikeo S, Morita M, et al
    Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
    BMC Cancer. 2017;17:797.
    PubMed     Text format     Abstract available


  73. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
    BMC Cancer. 2017;17:800.
    PubMed     Text format     Abstract available


  74. HIGUCHI Y, Motoki T, Ishida H, Kanamitsu K, et al
    Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    BMC Cancer. 2017;17:775.
    PubMed     Text format     Abstract available


  75. KRISHNASWAMY S, Mohammed AK, Tripathi G, Alokail MS, et al
    Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
    BMC Cancer. 2017;17:738.
    PubMed     Text format     Abstract available


  76. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Text format     Abstract available


  77. WANG T, Chen X, Qiao W, Kong L, et al
    Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer.
    BMC Cancer. 2017;17:719.
    PubMed     Text format     Abstract available


    October 2017
  78. TANAKA H, Taima K, Morimoto T, Tanaka Y, et al
    A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    BMC Cancer. 2017;17:683.
    PubMed     Text format     Abstract available


    September 2017
  79. EDBROOKE L, Aranda S, Granger CL, McDonald CF, et al
    Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer - protocol for a phase II randomised controlled trial.
    BMC Cancer. 2017;17:663.
    PubMed     Text format     Abstract available


  80. JIN R, Chen X, Han D, Luo X, et al
    Clusterin modulates transdifferentiation of non-small-cell lung cancer.
    BMC Cancer. 2017;17:661.
    PubMed     Text format     Abstract available


  81. URUSHIYAMA H, Jo T, Yasunaga H, Yamauchi Y, et al
    Adjuvant chemotherapy versus chemoradiotherapy for small cell lung cancer with lymph node metastasis: a retrospective observational study with use of a national database in Japan.
    BMC Cancer. 2017;17:613.
    PubMed     Text format     Abstract available


    August 2017
  82. WANG X, Su S, Li S, Bao H, et al
    Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China.
    BMC Cancer. 2017;17:603.
    PubMed     Text format     Abstract available


  83. AARELEID T, Zimmermann ML, Baburin A, Innos K, et al
    Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study.
    BMC Cancer. 2017;17:596.
    PubMed     Text format     Abstract available


  84. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Text format     Abstract available


  85. HATA Y, Kiribayashi T, Kishi K, Nagashima M, et al
    Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
    BMC Cancer. 2017;17:581.
    PubMed     Text format     Abstract available


  86. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2017;17:571.
    PubMed     Text format     Abstract available


  87. SZTANKAY M, Giesinger JM, Zabernigg A, Krempler E, et al
    Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
    BMC Cancer. 2017;17:565.
    PubMed     Text format     Abstract available


  88. LEE YS, Nam HS, Lim JH, Kim JS, et al
    Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
    BMC Cancer. 2017;17:557.
    PubMed     Text format     Abstract available


    July 2017
  89. FUGAZZARO S, Costi S, Mainini C, Kopliku B, et al
    PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.
    BMC Cancer. 2017;17:508.
    PubMed     Text format     Abstract available


  90. WANG Q, Cheng Y, Wang Y, Fan Y, et al
    Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    BMC Cancer. 2017;17:492.
    PubMed     Text format     Abstract available


  91. KIM EY, Jung JY, Kim A, Kim K, et al
    Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.
    BMC Cancer. 2017;17:467.
    PubMed     Text format     Abstract available


  92. ZHOU Q, Song Y, Zhang X, Chen GY, et al
    A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    BMC Cancer. 2017;17:462.
    PubMed     Text format     Abstract available


    June 2017
  93. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Text format     Abstract available


  94. SNEDDON S, Patch AM, Dick IM, Kazakoff S, et al
    Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
    BMC Cancer. 2017;17:396.
    PubMed     Text format     Abstract available


    May 2017
  95. JOHNEN G, Gawrych K, Raiko I, Casjens S, et al
    Calretinin as a blood-based biomarker for mesothelioma.
    BMC Cancer. 2017;17:386.
    PubMed     Text format     Abstract available


  96. MISUMI Y, Okamoto H, Sasaki J, Masuda N, et al
    Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    BMC Cancer. 2017;17:377.
    PubMed     Text format     Abstract available


  97. KULASINGHE A, Perry C, Kenny L, Warkiani ME, et al
    PD-L1 expressing circulating tumour cells in head and neck cancers.
    BMC Cancer. 2017;17:333.
    PubMed     Text format     Abstract available


  98. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Text format     Abstract available


  99. YEO J, Crawford EL, Zhang X, Khuder S, et al
    A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
    BMC Cancer. 2017;17:301.
    PubMed     Text format     Abstract available


  100. NAKAMURA K, Kato M, Shukuya T, Mori K, et al
    Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    BMC Cancer. 2017;17:302.
    PubMed     Text format     Abstract available


  101. SHIMAZU K, Tada Y, Morinaga T, Shingyoji M, et al
    Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    BMC Cancer. 2017;17:309.
    PubMed     Text format     Abstract available


  102. TAYLOR SA, Mallett S, Miles A, Beare S, et al
    Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
    BMC Cancer. 2017;17:299.
    PubMed     Text format     Abstract available


    April 2017
  103. OHSAKI Y, Sasaki T, Endo S, Kitada M, et al
    Observation of Zn-photoprotoporphyrin red Autofluorescence in human bronchial cancer using color-fluorescence endoscopy.
    BMC Cancer. 2017;17:289.
    PubMed     Text format     Abstract available


  104. ZHOU T, Zhan J, Fang W, Zhao Y, et al
    Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).
    BMC Cancer. 2017;17:269.
    PubMed     Text format     Abstract available


  105. ZHAO F, Zhou Y, Ge PF, Huang CJ, et al
    A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer.
    BMC Cancer. 2017;17:267.
    PubMed     Text format     Abstract available


  106. HORIMASU Y, Ishikawa N, Tanaka S, Hirano C, et al
    MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.
    BMC Cancer. 2017;17:263.
    PubMed     Text format     Abstract available


  107. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    PubMed     Text format     Abstract available


  108. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Text format     Abstract available


    March 2017
  109. FRUGTNIET BA, Martin TA, Zhang L, Jiang WG, et al
    Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion.
    BMC Cancer. 2017;17:224.
    PubMed     Text format     Abstract available


  110. AK G, Tada Y, Shimada H, Metintas S, et al
    Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    BMC Cancer. 2017;17:212.
    PubMed     Text format     Abstract available


  111. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Text format     Abstract available


  112. WANG JZ, Xiang JJ, Wu LG, Bai YS, et al
    A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    BMC Cancer. 2017;17:167.
    PubMed     Text format     Abstract available


    February 2017
  113. FERNANDEZ-MARTINEZ L, Villegas JA, Santamaria I, Pitiot AS, et al
    Identification of somatic and germ-line DICER1 mutations in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome pedigree.
    BMC Cancer. 2017;17:146.
    PubMed     Text format     Abstract available


  114. MA J, Yang QL, Ling Y
    Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC Cancer. 2017;17:132.
    PubMed     Text format     Abstract available


  115. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Text format     Abstract available


    January 2017
  116. WANG L, Liu D, Lu J, Zhang S, et al
    The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy.
    BMC Cancer. 2017;17:75.
    PubMed     Text format     Abstract available


  117. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Text format     Abstract available


  118. GOTO T, Hirotsu Y, Mochizuki H, Nakagomi T, et al
    Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report.
    BMC Cancer. 2017;17:65.
    PubMed     Text format     Abstract available


  119. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
    Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    BMC Cancer. 2017;17:48.
    PubMed     Text format     Abstract available


  120. MARRER E, Jolly D, Arveux P, Lejeune C, et al
    Incidence of solitary pulmonary nodules in Northeastern France: a population-based study in five regions.
    BMC Cancer. 2017;17:47.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: